Enhanced Vergence Recovery Convalescence Using AI-Adaptive Dynamic Vergence Testing Platform

The present inventive concept relates to an enhanced dynamic vergence testing platform for vergence recovery convalescence, incorporating artificial intelligence, machine learning, and virtual reality technology to improve the accuracy, efficiency, and accessibility of vergence dysfunction diagnosis and treatment.

The original patent, titled 'Vergence recovery convalescence using dynamic vergence testing platform including 3D head mounted display system with integrated eye tracking technology,' provides a non-invasive, clinical, objective testing of vergence dysfunction. However, the existing platform has limitations in adapting to individual subjects' responses, lacks personalized treatment protocols, and may not provide an engaging testing experience. The present inventive concept addresses these limitations by introducing AI-adaptive testing protocols, machine learning-based prediction algorithms, and immersive virtual reality technology.

The enhanced dynamic vergence testing platform comprises a 3D head-mounted display system with integrated eye tracking technology, a machine learning algorithm, and artificial intelligence. The AI-adaptive testing protocol adjusts the testing sequence based on the subject's response to previous tests, ensuring a more accurate diagnosis of vergence dysfunction. The machine learning algorithm predicts the likelihood of vergence dysfunction, enabling early intervention and personalized treatment. The virtual reality technology provides a more immersive and engaging testing experience, increasing the accuracy of test results. Additionally, the platform can be integrated with a cloud-based system for remote data analysis and reporting, enabling more convenient and accessible testing.

The new claims introduce the use of artificial intelligence, machine learning, and virtual reality technology to improve the dynamic vergence testing platform. The AI-adaptive testing protocol, machine learning-based prediction algorithm, and immersive virtual reality technology provide a novel and non-obvious solution to the limitations of the original patent.

Alternative embodiments of the inventive concept may include using different types of AI algorithms, incorporating additional sensors or tracking technologies, or integrating the platform with other diagnostic tools. Variations of the platform may be designed for specific age groups, such as pediatric or geriatric populations, or for specific types of vergence dysfunction.

The enhanced dynamic vergence testing platform has significant commercial potential in the healthcare industry, particularly in the fields of ophthalmology, optometry, and neurology. The platform can be marketed as a diagnostic tool for early detection and treatment of vergence dysfunction, providing a competitive advantage in the market. Additionally, the platform's remote testing capabilities can expand its market reach, making it more accessible to a wider range of patients.